Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients-Reference-Cited by-同舟云学术

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Published:1997-12 Issue:12 Volume:41 Page:2797-2799
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Piscitelli S C¹,Figg W D¹,Hahn B¹,Kelly G¹,Thomas S¹,Walker R E¹

Affiliation:

1. Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA. spisc@nih.gov

Abstract

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.41.12.2797

Reference21 articles.

1. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review;Ball S. C.;Am. J. Gastroenterol.,1997

2. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers;Chen T.;Drug Metab. Dispos.,1989

3. D'Argenio D. Z. and A. Schumitzky. 1990. ADAPT II user's guide. Biomedical Simulations Resource University of Southern California Los Angeles.

4. Pentoxyfylline suppression of tumor necrosis factor gene transcription;Doherty G. M.;Surgery,1991

5. Gibaldi M. and D. Perrier. 1982. Pharmacokinetics 2nd ed. Marcel Dekker Inc. New York N.Y.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies;European Journal of Pharmaceutical Sciences;2019-12

2. Stability Study of a Thalidomide Suspension;Journal of Pharmacy Practice and Research;2012-06

3. Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma;Current Cancer Drug Targets;2012-04-01

4. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates;Cancer Chemotherapy and Pharmacology;2011-11-23

5. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production;Blood Cancer Journal;2011-10